Yahoo! Finance Search - Finance Home - Yahoo! - Help

Thursday, October 23 2014 4:46am ET - U.S. Markets open in 4 hours and 44 minutes.
Industry Center - Drug Manufacturers - Other
Industry Center > Drug Manufacturers - Other > News
More On This Industry
· Summary
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Drug Manufacturers - Other News
Latest News
Tuesday, Oct 21, 2014
·Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)
GlobeNewswire - Tue 6:00 pm ET
·Cumberland Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 4, 2014
PR Newswire - Tue 4:05 pm ET
·Allergan keeps a few secrets, court filing shows
at MarketWatch - Tue 3:04 pm ET
·Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT
PR Newswire - Tue 2:09 pm ET
·Valeant, Ackman: Allergan Spread 'Misleading' Info in Takeover Fight
at The Wall Street Journal Online - Tue 12:29 pm ET
·Trade-Ideas: Allergan (AGN) Is Today's Momo Momentum Stock
at - Tue 10:50 am ET
·Allergan says it stands by statements on Valeant
Reuters - Tue 10:45 am ET
·United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014
PR Newswire - Tue 6:00 am ET
·Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
Business Wire - Tue 6:00 am ET
Monday, Oct 20, 2014
·Ackman, Valeant lawyers say Allergan CEO oversaw campaign to discredit Valeant
Reuters - Mon Oct 20
·CANADA STOCKS-TSX advances with gold miners, Valeant
Reuters - Mon Oct 20
·Endo to Announce Third Quarter 2014 Financial Results on November 5, 2014
PR Newswire - Mon Oct 20
·Allergan files rebuttal to Valeant earnings
at MarketWatch - Mon Oct 20
·Jim Cramer: Valeant Pharmaceuticals and Allergan Are Winners
at - Mon Oct 20
·[$$] Valeant Pushes Business Strength
at The Wall Street Journal Online - Mon Oct 20
·RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
PR Newswire - Mon Oct 20
·[video] Cramer's Stop Trading: Valeant & Allergan
at CNBC - Mon Oct 20
·Valeant may raise Allergan bid, says it won't walk away
Reuters - Mon Oct 20
·Valeant reports better-than-expected profit, raises forecast
Reuters - Mon Oct 20
·Takeda and Orexigen Announce Availability of CONTRAVE┬« (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults
PR Newswire - Mon Oct 20
More Latest News...
Sponsor Results
Professional Statistician
All areas of research. Free initial consultation. 877-461-7226
Paperless Reg Docs
Secure online portal for clinical study start-up.
College Degree Online
Get Degree With $5,730 University or College Grant if Qualify. Act Now.
(What's This?)

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Other Headlines
More Finance RSS Feeds

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?